<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04445571</url>
  </required_header>
  <id_info>
    <org_study_id>180367</org_study_id>
    <nct_id>NCT04445571</nct_id>
  </id_info>
  <brief_title>Surfactant Administration by Insure or Thin Catheter</brief_title>
  <acronym>SAINT</acronym>
  <official_title>Surfactant Administration by Insure or Thin Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates the efficacy and safety of surfactant administration with thin catheter
      technique together with analgesic premedication in comparison with the established
      INSURE-strategy. It will provide valuable knowledge to improve clinical methodology and
      enhance lung protective treatment strategies for preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare two approaches for surfactant administration during CPAP in preterm infants, the
      INSURE and the LISA technique, using premedication intubation protocols, and investigate
      aspects of safety, stress and pain, timely administration of the drug, response in
      oxygenation and pulmonary outcome.

      Our study asks whether (P) among infants born &lt;32 weeks' gestation with RDS (I) does
      surfactant administration with LISA and analgesia premedication (C) versus surfactant
      administration according to the INSURE protocol (O) improve oxygenation and reduce the rate
      of respiratory failure and need for intubation and mechanical ventilation (T) within 48 hours
      of the procedure

      Primary outcomes:

        1. Positive effect: Oxygenation measured as arterial to alveolar ratio (a/A ratio) at 24
           hours post-procedure.

        2. Negative effect: Need for mechanical ventilation (MV) within 48 hours post-procedure.

      Safety outcomes:

        1. Time from meeting the FiO2 or a/A ratio criteria for surfactant treatment until
           surfactant administration

        2. Number of tries before successful intubation/placement of catheter

        3. Positive pressure ventilation during the procedure - yes/no/duration (minutes)

        4. Stress and pain (changes in heart rate, blood pressure and BIIP-scale)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenation</measure>
    <time_frame>24 hours post-procedure</time_frame>
    <description>Arterial to alveolar ratio (a/A ratio)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>48 hours post-procedure</time_frame>
    <description>Need for intubation and mechanical ventilation (MV)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilatory support</measure>
    <time_frame>Discharge</time_frame>
    <description>Duration of MV (hours), CPAP (days), Oxygen (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Discharge</time_frame>
    <description>Incidence of air leaks, bronchopulmonary dysplasia, Systemic hypotension, retinopathy, necrotizing entercolitis, intraventricular hemorrhage, persistent duct</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Discharge</time_frame>
    <description>Death or composite outcome death/BPD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Discharge</time_frame>
    <description>Number of days in NICU and total in neonatal care, including home care</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Delay time</measure>
    <time_frame>24 hours</time_frame>
    <description>Time from meeting the FiO2 or a/A ratio criteria for surfactant treatment until surfactant administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Intubation attempts</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of tries before successful intubation/placement of catheter</description>
  </other_outcome>
  <other_outcome>
    <measure>PPV</measure>
    <time_frame>24 hours</time_frame>
    <description>Positive pressure ventilation during the procedure - yes/no/duration (minutes)</description>
  </other_outcome>
  <other_outcome>
    <measure>Stress and pain</measure>
    <time_frame>24 hours</time_frame>
    <description>Changes in heart rate, blood pressure and BIIP-scales</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>RDS of Prematurity</condition>
  <condition>Surfactant Deficiency Syndrome Neonatal</condition>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>INSURE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surfactant administration by Intubation-surfactant-extubation to CPAP according to standard protocol including premedication with analgesia and sedation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LISA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surfactant administration by thin catheter during spontaneous breathing and continued CPAP according to set protocol including premedication with analgesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thin catheter technique or standard ET-tube for surfactant administration</intervention_name>
    <description>Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.</description>
    <arm_group_label>INSURE</arm_group_label>
    <arm_group_label>LISA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants born before 32 completed weeks of gestation on CPAP, with clinical and
             radiological signs of RDS and need for surfactant treatment.

        Exclusion Criteria:

          -  Infants requiring surfactant as part of delivery room resuscitation are not eligible.

        Infants will be excluded from the final analysis if they have a congenital abnormality or
        condition that might have an adverse effect on breathing or ventilation, including:
        congenital diaphragmatic hernia; tracheo-oesophageal fistula or cyanotic heart disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kajsa Bohlin, MD</last_name>
    <phone>+46858580000</phone>
    <phone_ext>81356</phone_ext>
    <email>kajsa.bohlin@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mats Blennow, MD</last_name>
    <phone>+46858580000</phone>
    <phone_ext>81428</phone_ext>
    <email>mats.blennow@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kajsa Bohlin, MD</last_name>
      <phone>0858580000</phone>
      <phone_ext>81356</phone_ext>
      <email>kajsa.bohlin@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Mats Blennow, MD</last_name>
      <phone>0858580000</phone>
      <phone_ext>81428</phone_ext>
      <email>mats.blennow@ki.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Kajsa Bohlin</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>LISA (Less invasive surfactant administration)</keyword>
  <keyword>INSURE</keyword>
  <keyword>CPAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

